{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:47:56Z","timestamp":1793936876103,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5\u00a0mg\/d in adults or 0.07\u20130.1\u00a0mg\/(kg\u00a0d) in children was administered from the day of neutrophil engraftment to 100\u00a0days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, <jats:italic>P<\/jats:italic>\u2009=\u20090.046) and grade II\u2013IV aGVHD (42.9 vs. 12.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.514), disease-free survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.691), and cumulative platelet transfusion within 100\u00a0days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated.<\/jats:p>","DOI":"10.1038\/s41598-021-88080-3","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T10:04:56Z","timestamp":1618826696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Binglei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingling","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"issue":"9","key":"88080_CR1","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.bbmt.2018.05.009","volume":"24","author":"J Dalle","year":"2018","unstructured":"Dalle, J. et al. Allogeneic Stem Cell Transplantation from HLA-mismatched donors for pediatric patients with acute lymphoblastic Leukemia treated according to the 2003 BFM and 2007 international BFM studies: impact of disease risk on outcomes. Biol. Blood Marrow Transpl. 24(9), 1848\u20131855 (2018).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"1","key":"88080_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bbmt.2015.09.008","volume":"22","author":"A Lazaryan","year":"2016","unstructured":"Lazaryan, A. et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol. Blood Marrow Transpl. 22(1), 134\u2013140 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"1","key":"88080_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia, M. et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119(1), 296\u2013307 (2012).","journal-title":"Blood"},{"issue":"1","key":"88080_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu, L. et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China\u2014recommendations from the Chinese Society of Hematology. J. Hematol. Oncol. 11(1), 33 (2018).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"88080_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","volume":"12","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J. Hematol. Oncol. 12(1), 88 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"88080_CR6","doi-asserted-by":"crossref","unstructured":"Montoro J, Pi\u00f1ana J, Hern\u00e1ndez-Boluda J, Hernani R, Lorenzo I, P\u00e9rez A et al.. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transpl. 2020.","DOI":"10.1038\/s41409-020-0921-6"},{"key":"88080_CR7","doi-asserted-by":"crossref","unstructured":"Liu S, Zhang X, Xu L, Wang Y, Yan C, Chen H et al.. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: updated experience from a large-scale study. Am. J. Hematol. 2020.","DOI":"10.1002\/ajh.25839"},{"issue":"1","key":"88080_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-019-0710-0","volume":"12","author":"K Wang","year":"2019","unstructured":"Wang, K. et al. Early myeloid-derived suppressor cells (HLA-DR\u2212\/lowCD33+CD16\u2212) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. J. Hematol. Oncol. 12(1), 31 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"88080_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12935-020-01193-z","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou, X., Jin, N., Wang, F. & Chen, B. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease. Cancer Cell Int. 20, 114 (2020).","journal-title":"Cancer Cell Int."},{"issue":"15","key":"88080_CR10","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama, A. et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15), 3109\u20133117 (2010).","journal-title":"Blood"},{"issue":"24","key":"88080_CR11","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl, S. et al. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood 123(24), 3832\u20133842 (2014).","journal-title":"Blood"},{"issue":"16","key":"88080_CR12","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","volume":"21","author":"C Carniti","year":"2015","unstructured":"Carniti, C. et al. Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin. Cancer Res. 21(16), 3740\u20133749 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"88080_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka, D. et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist 25(2), e328\u2013e334 (2020).","journal-title":"Oncologist"},{"issue":"5","key":"88080_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/bjh.14679","volume":"181","author":"D Assouan","year":"2018","unstructured":"Assouan, D. et al. Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease. Br. J. Haematol. 181(5), 687\u2013689 (2018).","journal-title":"Br. J. Haematol."},{"issue":"19","key":"88080_CR15","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser, R. et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N. Engl. J. Med. 382(19), 1800\u20131810 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"88080_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","volume":"25","author":"S Abedin","year":"2019","unstructured":"Abedin, S. et al. Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 25(8), 1689\u20131694 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"20","key":"88080_CR17","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.2020005364","volume":"135","author":"A Risitano","year":"2020","unstructured":"Risitano, A. & Peffault, D. L. R. Ruxolitinib for steroid-resistant acute GVHD. Blood 135(20), 1721\u20131722 (2020).","journal-title":"Blood"},{"issue":"3","key":"88080_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","volume":"55","author":"V Escamilla G\u00f3mez","year":"2020","unstructured":"Escamilla G\u00f3mez, V. et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transpl. 55(3), 641\u2013648 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"88080_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40164-020-00162-6","volume":"9","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and\/or relapsed childhood acute leukemia: a randomized trial. Exp. Hematol. Oncol. 9, 5 (2020).","journal-title":"Exp. Hematol. Oncol."},{"key":"88080_CR20","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J et al.. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995; 15(6): 825\u20138."},{"key":"88080_CR21","doi-asserted-by":"crossref","unstructured":"Shulman H, Sullivan K, Weiden P, McDonald G, Striker G, Sale G et al.. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am. J. Med. 1980; 69(2): 204\u201317.","DOI":"10.1016\/0002-9343(80)90380-0"},{"key":"88080_CR22","doi-asserted-by":"crossref","unstructured":"Martin P, Lee S, Przepiorka D, Horowitz M, Koreth J, Vogelsang G et al.. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol. Blood Marrow Transpl. 2015; 21(8): 1343\u201359.","DOI":"10.1016\/j.bbmt.2015.05.004"},{"issue":"2","key":"88080_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","volume":"49","author":"T Ruutu","year":"2014","unstructured":"Ruutu, T. et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transpl. 49(2), 168\u2013173 (2014).","journal-title":"Bone Marrow Transpl."},{"issue":"12","key":"88080_CR24","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/bmt.2016.256","volume":"51","author":"Y Mori","year":"2016","unstructured":"Mori, Y. et al. Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transpl. 51(12), 1584\u20131587 (2016).","journal-title":"Bone Marrow Transpl."},{"key":"88080_CR25","doi-asserted-by":"crossref","unstructured":"Zhao Y, Wu H, Shi J, Luo Y, Li X, Lan J et al.. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study. Am. J. Hematol. 2020.","DOI":"10.1002\/ajh.25898"},{"issue":"10","key":"88080_CR26","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser, R. et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10), 2062\u20132068 (2015).","journal-title":"Leukemia"},{"key":"88080_CR27","doi-asserted-by":"crossref","unstructured":"Morozova E, Barabanshikova M, Moiseev I, Shakirova A, Barhatov I, Ushal I et al.. A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis. Acta Haematol. Basel 2020: 1\u20138.","DOI":"10.1159\/000506758"},{"issue":"5","key":"88080_CR28","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/j.bbmt.2020.01.012","volume":"26","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Calcineurin inhibitors replacement by ruxolitinib as graft-versus-host disease prophylaxis for patients after allogeneic stem cell transplantation. Biol. Blood Marrow Transpl. 26(5), e128\u2013e133 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"88080_CR29","doi-asserted-by":"crossref","unstructured":"Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T et al.. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur. J. Haematol. 2018; 101(3): 305\u2013317.","DOI":"10.1111\/ejh.13099"},{"issue":"5","key":"88080_CR30","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.bbmt.2019.11.029","volume":"26","author":"N Yoshida","year":"2020","unstructured":"Yoshida, N. et al. Clinical outcomes after allogeneic hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: a report from the Japan society for hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 26(5), 902\u2013910 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"6","key":"88080_CR31","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1002\/ajh.23998","volume":"90","author":"A Busca","year":"2015","unstructured":"Busca, A. et al. The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. Am. J. Hematol. 90(6), E117\u2013E121 (2015).","journal-title":"Am. J. Hematol."},{"key":"88080_CR32","doi-asserted-by":"crossref","unstructured":"Kaito S, Najima Y, Harada K, Fukuda T, Noguchi Y, Ikegame K et al.. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype. Bone Marrow Transpl. 2020; 55(7): 1337\u20131346.","DOI":"10.1038\/s41409-020-0816-6"},{"issue":"4","key":"88080_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbmt.2014.01.009","volume":"20","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza, B. et al. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol. Blood Marrow Transpl. 20(4), 549\u2013555 (2014).","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88080-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:02:37Z","timestamp":1670050957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88080-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88080"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88080-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"10 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8501"}}